The quarter mostly delivered against an already visible catalyst schedule, but added meaningful execution proof. RGX-202’s Phase III AFFINITY DUCHENNE trial met its primary endpoint with high statistical significance, enrollment finished ahead of schedule, and the company remains on track to begin the BLA submission in Q3 2026. That is better than a simple progress update, although the BLA timing and potential 2027 approval were already part of the standing story. The more incremental positive is the FDA’s July Type A meeting, which reaffirmed that no additional RGX-121 studies are required before BLA resubmission. (RGX-202 program highlights; RGX-121 program highlights)
The financial headline is strong but largely nonrecurring. Revenue and earnings swung sharply higher because the first NAAVIGATE patient triggered a $100.0 million AbbVie milestone, not because the underlying business suddenly became profitable. The milestone also partially masked a $16.7 million decline in ZOLGENSMA royalty revenue after U.S. patent expiration. (Revenues; Income Statement)
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $108.0 million | $21.4 million |
| R&D expense | $56.1 million | $59.5 million |
| G&A expense | $21.6 million | $19.9 million |
| Net income / (loss) | $22.7 million | $(70.9) million |
| Basic and diluted EPS | $0.43 | $(1.38) |
| Cash, equivalents and marketable securities at quarter-end | $105.5 million | — |
| Pro forma cash after July financing and milestone | Approximately $313 million | — |
Funding risk is materially reduced, but dilution is part of the tradeoff. The $100.0 million AbbVie payment and approximately $107.8 million of net offering proceeds extend the stated cash runway into Q4 2027 and fund the planned ex-U.S. AFFINITY RISE study. That improves the company’s ability to reach multiple 2026–2027 catalysts without an immediate financing overhang, while the equity offering adds dilution and the runway still depends on the current operating plan. (Cash Position; Financial Guidance)
The net read is modestly better than the pre-filing setup, not a wholesale reset. The filing confirms several expected milestones, but the combination of a positive pivotal RGX-202 readout, FDA clarity for RGX-121, durable longer-term sura-vec data, and a newly strengthened balance sheet improves confidence in execution ahead of the more decisive catalysts: Q4 2026 wet-AMD topline data and the RGX-202 and RGX-121 regulatory submissions. The quarter’s reported profit should not be treated as recurring operating earnings. (RGX-202 program highlights; Retinal disease program highlights; RGX-121 program highlights)
Read the original 8-K on SEC EDGAR ↗